Audentes stock: buy or sell?

BOLD stock price: $59.97 -0.02% At close on January 14th, 2020

Updated on:
January 14th, 2020

3

After topping to all time highs on January, Audentes stayed stable -0.02% on January to $59.97.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States.

Should I buy Audentes stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Check the only buy setup that matches with Audentes stock now:

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MAYes

Is Audentes Therapeutics stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for BOLD stock for the last 30 days.

Audentes stock analysis

Daily outlook

After reaching all time highs on January, Audentes stayed stable -0.02% on January to $59.97.

Audentes Therapeutics stayed steady -0.02% on January to $59.97 after marking all time highs on January. Since SMA100d and SMA200d crossed up on January, BOLD price slid a -0.02%. Since price and SMA200d lines crossed up on December, BOLD climbed $31.36 (109.61%). On January, BOLD hit new all time highs, pushing higher previous ATH of $59.95 recorded on December. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

BOLD stock chart (daily)

Weekly outlook

Audentes Therapeutics stayed constant a neutral 0.00% this week. Early December BOLD boosted an extraordinary 51.00% in just one week. Counting this, it's been 5 climbing weeks in a row, soaring a 0.96%.

Not so far away is the last all-time high Audentes marked early January. Early January, SMA20w and SMA40w crossed up triggering a rise of 0.18%. Since price and SMA40w lines crossed up early December, BOLD climbed $30.94 (106.58%).

BOLD stock chart (weekly)

Audentes stock price history

Audentes stock went public on July 20th, 2016 with a price of $19.001. Since then, BOLD stock surged a 215.60%, with a yearly average of 71.90%. If you had invested $1,000 in Audentes stock in 2016, it would worth $2,156.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Audentes stock historical price chart

BOLD stock reached all-time highs on January with a price of $60.00.

Audentes stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' BOLD stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price target for Audentes Therapeutics stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Audentes failed to meet the expectations of the analysts and reported a fatal EPS of $-0.84 per share when experts were expecting $-0.92.
BOLD earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.83n/a
2017-Q2-n/a-0.87n/a
2017-Q32017-11-08-0.88n/an/a
2017-Q42018-03-08-0.92-0.82n/a
2018-Q12018-05-09-0.81-0.74n/a
2018-Q22018-08-07-0.78-0.85n/a
2018-Q32018-11-06-0.88-0.97n/a
2018-Q42019-02-27-0.92-0.84n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , Audentes annual revenues to M dollars from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .

BOLD annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-35.59 million with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Audentes sales marked a neutral move and stayed stable a nan%. Looking back to recent quarterly results, Audentes Therapeutics posted 7 positive quarters in a row.
BOLD quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Audentes ownership

When you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Audentes Therapeutics, 7.30% of all outstanding shares are owned by its staff.

Bearish positions for BOLD stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Audentes:

BOLD
Market cap$2.8 B
Total shares45.9 M
Float shares37.0 M
  - Institutional holdings (%)100.1%
  - Insider holdings (%)7.3%
Shares in short selling0.0%

Audentes summary

Tuesday, January 14th, 2020
Open$59.98
Close$59.97
Day range$59.97 - $59.99
Previous close$59.98
Session gain-0.02%
Average true range$0.10
50d mov avg$46.24
100d mov avg$37.74
200d mov avg$37.73
Daily pattern
Weekly pattern

Audentes performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Audentes Therapeutics against in the following table:
Stock3m6m12m
BOLDAudentes Therapeu...123.35%58.23%144.18%

Audentes competitors

Unfortunately, we could not find any public company that could be defined as Audentes competitor. This doesn't mean Audentes does not have any competitor in the market, it's just we could not detected it.